Back to Search
Start Over
Varenicline, an [alpha]4[beta]2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial
- Source :
- JAMA, The Journal of the American Medical Association. July 5, 2006, Vol. 296 Issue 1, p47, 9 p.
- Publication Year :
- 2006
-
Abstract
- A study was conducted to assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. It was found that varenicline was significantly more efficient than placebo for smoking cessation at all time points and significantly more effective than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
- Subjects :
- Smoking cessation programs -- Health aspects
Smoking -- Drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 00987484
- Volume :
- 296
- Issue :
- 1
- Database :
- Gale General OneFile
- Journal :
- JAMA, The Journal of the American Medical Association
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.149327215